VCA
ADMA icon

Verdence Capital Advisors’s ADMA Biologics ADMA Stock Holding History

Verdence Capital Advisors’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-10,786
Closed -$48.8K – 587
2023
Q4 		$48.8K Buy
10,786
+368
+4% +$1.36K ﹤0.01% 560
2023
Q3 		$37.3K Sell
10,418
-895
-8% -$3.44K ﹤0.01% 552
2023
Q2 		$41.7K Buy
11,313
+784
+7% +$2.91K ﹤0.01% 528
2023
Q1 		$34.9K Sell
10,529
-1,419
-12% -$4.91K ﹤0.01% 530
2022
Q4 		$46.4K Buy
+11,948
New +$36.9K 0.01% 491

Other funds holding ADMA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
AIC
AWM Investment Company New York $1.15B AUM 201.65% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Verdence Capital Advisors's ADMA Position: Q1 2024 in Review

Verdence Capital Advisors sold out of ADMA Biologics (ADMA) in Q1 2024, closing a stake of 10,786 shares — an estimated $48.8K sold.

Verdence Capital Advisors first reported a position in ADMA in Q4 2022 and held it in 5 quarters. The position peaked at $48.8K in Q4 2023. 214 funds tracked by Wall St. Rank hold ADMA as of Q1 2024.

  • Verdence Capital Advisors reported no remaining ADMA Biologics position as of Q1 2024 after selling out during the quarter.
  • Verdence Capital Advisors sold 10,786 ADMA Biologics shares in Q1 2024, an estimated $48.8K.
  • Verdence Capital Advisors first reported a position in ADMA Biologics in Q4 2022 and held it in 5 quarters.
  • Verdence Capital Advisors's ADMA Biologics position peaked at $48.8K in Q4 2023.
  • 214 funds tracked by Wall St. Rank held ADMA Biologics as of Q1 2024.

Based on Verdence Capital Advisors's 13F filing for Q1 2024, filed 25 Apr 2024.